Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03477435 · ClinicalTrials.gov registry record · NA

Comparing an Opt-out to an opt-in Approach for Smoking Cessation in VA Primary Care Clinics

A NA study of Tobacco Use, sponsored by VA Office of Research and Development.

Active
Registry status
NA
Development phase
1,365
Enrollment target
1
Study location

NCT03477435: Active NA study of Tobacco Use, sponsored by VA Office of Research and Development.

NCT03477435 is a NA study of Tobacco Use that is active but no longer recruiting, run by VA Office of Research and Development. The registered enrollment target is 1,365 participants, above the 361-participant average among 76 other Tobacco Use trials with a reported enrollment target (278% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03477435, a NA study of Tobacco Use, is active but no longer recruiting, sponsored by VA Office of Research and Development.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
1,365 participants
Enrollment target
1
Study location

Study Summary

The investigators propose a Type I hybrid effectiveness/implementation study to evaluate two population-based approaches for increasing use of Quitlines and text messaging at two VA sites. Specifically, the investigators will test the default bias, examining whether an opt-out approach to referral is more effective than an opt-in approach. The investigators will randomly assign teams to either an opt-out or opt-in approach to referring smokers to treatment. In the opt-out approach, the default is that everyone is referred to treatment unless they actively choose not to be. In the opt-in approach, people are offered treatment but must actively choose to enroll in it.

Primary Outcome

This outcome will be based on intervention process data. Note that we will measure both offering and accepting referral, but our outcome will be accepting referral.

Conditions Studied

Interventions

  • BEHAVIORAL Staff training and academic detailing

Study Locations (1)

New York

  • VA NY Harbor Healthcare System, New York, NY - New York

Trial Details

FieldValue
Enrollment Target 1,365 participants
Start Date 2019-08-28
Est. Completion 2026-04-01
Phase NA
VA Office of Research and Development

1,668 total trials

What the registry record for NCT03477435 still lists

NCT03477435 is an interventional study that assigns participants to a tested intervention. Its 1,365 participants enrollment target places it among the larger protocols in the corpus, above the 361-participant average among 76 other Tobacco Use trials with a reported enrollment target (278% higher).

The record links to 1 condition, with Tobacco Use appearing as the primary indexed condition, and to 1 intervention - of which Staff training and academic detailing is the first listed.

NCT03477435 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT03477435 about?

NCT03477435 is a clinical study titled "Comparing an Opt-out to an opt-in Approach for Smoking Cessation in VA Primary Care Clinics". The investigators propose a Type I hybrid effectiveness/implementation study to evaluate two population-based approaches for increasing use of Quitlines and text messaging at two VA sites. Specifically, the investigators will test the default bias, examining whether an opt-out approach to referral i...

What is the current status of trial NCT03477435?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 1,365 participants. The study started on 2019-08-28. Estimated completion is 2026-04-01.

What conditions does trial NCT03477435 study?

This clinical trial studies the following conditions: Tobacco Use.

What interventions are being tested in trial NCT03477435?

The interventions under investigation include: Staff training and academic detailing (BEHAVIORAL).

Who is sponsoring clinical trial NCT03477435?

This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03477435 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Tobacco Use

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03477435's enrollment target sits among peer trials

1,365 5th of 76 higher than 72 of 76 other Tobacco Use trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Tobacco Use trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02677064 · 1,365 participants

    Identify Barriers to Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Newly Diagnosed and Relapsed Acute Leukemia

  • NCT04489238 · 1,366 participants

    Collection of Information to Better Understand Young Onset Colorectal Cancer

  • NCT07256392 · 1,370 participants · Phase 3

    Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria

  • NCT05245227 · 1,358 participants · Phase 3

    Double Simultaneous Uterotonic Agents Versus Single Agent Regimen to Prevent Early Postpartum Hemorrhage

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03477435, the US trial registry maintained by the National Library of Medicine. NCT03477435 (large enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.